J. Berbis,

L. ,

M. Bénédicte, MCF)(06ème section)

T. Nicolas,

K. Gilles, PU-PH) BLAISE Didier

M. Jean-louis, PU-PH) COSTELLO Régis

O. Daniel, PU-PH) CHIARONI Jacques

E. Vivier,

G. ,

M. Pierre-emmanuel,

. Feron-françois, PR) (69ème section) VEY Norbert

B. Joseph,

G. Véronique,

D. Joëlle,

L. Marina,

D. Sophie, MCU-PH) LOOSVELD Marie

R. Philippe,

. Vely-frédéric, MCU-PH) POGGI Marjorie (MCF) (64ème section)

B. Françoise, MCF) 65ème section)

. Brouqui-philippe,

L. Georges,

P. ,

P. ,

L. Jean-christophe, PU-PH) BARTOLI Christophe

(. Parola-philippe and . Lucile,

. Stein-andréas,

B. Caroline, MCF) (1ère section) MILLION Matthieu

B. Sylvie,

D. Patrick,

D. Jean-marc,

F. Yves, (. Surnombre, and G. Brigitte,

B. Laurent,

. Viton-jean-michel,

H. Jean-robert,

L. ,

R. Pascal,

, SCHLEINITZ Nicolas

S. Irène,

E. Mikael,

. Gentile-gaëtan,

A. Sébastien, PR associé Méd. Gén. à mi-­-temps) BERLAND Yvon (PU-­-PH) Surnombre FILIPPI Simon (PR associé Méd. Gén. à mi-temps) BRUNET Philippe (PU-PH) BURTEY Stépahne

D. Bertrand,

J. Bargier, MCF associé Méd. Gén. À mi-temps) JOURDE CHICHE Noémie

. Bonnet-pierre-andré, MCF associé Méd. Gén à mi-temps) MOAL Valérie

C. Céline, MCF associé Méd. Gén. à temps plein) GUIDA Pierre (MCF associé Méd. Gén. à mi-temps)

J. Aurélie, MCF associé Méd. Gén. À mi-temps)

P. Llorca, Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res, Lancet Lond Engl. 22 août, vol.161, issue.2, p.63545, 2008.

, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5, 2013.

A. Hasan, P. Falkai, T. Wobrock, J. Lieberman, B. Glenthoj et al., World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects, World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry. févr, vol.14, issue.1, p.244, 2013.

S. Crettol and C. B. Eap, Cytochromes P450: génotypage et/ou phénotypage pour l'individualisation du traitement médicamenteux, Rev Mediacle Suisse. févr, 2013.

, Code de la santé publique-Article L3222-3. Code de la santé publique sept 24, 2018.

E. Spina and J. De-leon, Clinical applications of CYP genotyping in psychiatry, J Neural Transm, vol.122, issue.1, p.528, 1996.

S. R. Kay, A. Fiszbein, and L. A. Opler, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, vol.13, issue.2, p.26176, 1987.

O. Lingjaerde, U. G. Ahlfors, P. Bech, S. J. Dencker, and K. Elgen, The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients, Acta Psychiatr Scand Suppl, vol.334, p.1100, 1987.

, American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders

, American Psychiatric Association, 2013.

. Disponible,

J. Kane, G. Honigfeld, J. Singer, and H. Meltzer, Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine, Arch Gen Psychiatry. sept, vol.45, issue.9, p.78996, 1988.

J. E. Overall and D. R. Gorham, The Brief Psychiatric Rating Scale, Psychol Rep. 1 juin, vol.10, issue.3, p.799812, 1962.

D. M. Gardner, A. L. Murphy, O. Donnell, H. Centorrino, F. Baldessarini et al., International consensus study of antipsychotic dosing, Am J Psychiatry. juin, vol.167, issue.6, p.68693, 2010.

V. Danivas and G. Venkatasubramanian, Current perspectives on chlorpromazine equivalents: Comparing apples and oranges, Indian J Psychiatry, vol.55, issue.2, p.2078, 2013.

D. Delessert, V. Pomini, F. Grasset, and P. Baumann,

, L'Encephale. déc, vol.33, issue.6, p.90210, 2007.

J. Blaisdell, H. Mohrenweiser, J. Jackson, S. Ferguson, S. Coulter et al., Identification and functional characterization of new potentially defective alleles of human CYP2C19, Pharmacogenetics. déc, vol.12, issue.9, p.70311, 2002.

H. Fukushima-uesaka, Y. Saito, K. Maekawa, S. Ozawa, R. Hasegawa et al., Genetic variations and haplotypes of CYP2C19 in a Japanese population, Drug Metab Pharmacokinet. août, vol.20, issue.4, p.3007, 2005.

R. Y. Qumsieh, B. R. Ali, Y. M. Abdulrazzaq, O. Osman, N. A. Akawi et al., Identification of New Alleles and the Determination of Alleles and Genotypes Frequencies at the CYP2D6 Gene in Emiratis, PLOS ONE. 22 déc, vol.6, issue.12, p.28943, 2011.

J. J. Swen, M. Nijenhuis, A. De-boer, L. Grandia, A. H. Maitland-van-der-zee et al., Pharmacogenetics: from bench to byte-an update of guidelines, Clin Pharmacol Ther. mai, vol.89, issue.5, p.66273, 2011.

A. Gaedigk, M. Ingelman-sundberg, N. A. Miller, J. S. Leeder, M. Whirl-carrillo et al., The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database, Clin Pharmacol Ther. mars, vol.103, issue.3, p.28943, 2007.

K. T. Kivistö and H. K. Kroemer, Use of probe drugs as predictors of drug metabolism in humans, J Clin Pharmacol, vol.37, issue.S1, pp.40-48, 1997.

P. Berney and R. Casagrande, La mesure de la concentration des médicaments psychotropes à l'ère de la pharmacogénétique, 2004.

G. Jürgens, H. Rasmussen, T. Werge, K. Dalhoff, M. Nordentoft et al., Does the Medication Pattern Reflect the CYP2D6 Genotype in Patients With Diagnoses Within the Schizophrenic Spectrum?, J Clin Psychopharmacol. 22 déc, vol.32, p.1005, 2011.

D. Ravyn, V. Ravyn, R. Lowney, and H. A. Nasrallah, CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence, Schizophr Res. sept, vol.149, issue.13, p.114, 2013.

F. B. Kohlrausch, C. S. Gama, M. I. Lobato, P. Belmonte-de-abreu, and C. Sm,

A. Gesteira, Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics, Pharmacogenet Genomics. juill, vol.18, issue.7, p.599609, 2008.

J. De-leon, M. T. Susce, R. Pan, M. Fairchild, W. H. Koch et al., The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation, J Clin Psychiatry. janv, vol.66, issue.1, p.1527, 2005.

J. Brockmöller, J. Kirchheiner, J. Schmider, S. Walter, C. Sachse et al., The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment, Clin Pharmacol Ther, vol.72, issue.4, 2002.

Z. Hashemizadeh, S. A. Malek-hosseini, and P. Badiee, Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses, Int J Organ Transplant Med, vol.11, issue.1, p.2733, 2011.

J. Sirot, E. Knezevic, B. Morena, G. P. Harenberg, S. Oneda et al., ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine, J Clin Psychopharmacol. août, vol.29, issue.4, p.31926, 2009.

W. H. Chang, S. K. Lin, H. Y. Lane, W. H. Hu, M. W. Jann et al., Clozapine dosages and plasma drug concentrations, J Formos Med Assoc Taiwan Yi Zhi. août, vol.96, issue.8, p.599605, 1997.

S. A. Scott, K. Sangkuhl, E. E. Gardner, C. M. Stein, J. Hulot et al., Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy, Clin Pharmacol Ther. août, vol.90, issue.2, p.32832, 2011.

C. F. Thorn, E. Aklillu, T. E. Klein, R. B. Altman, K. I. Melkersson et al., PharmGKB summary: very important pharmacogene information for CYP1A2, Pharmacogenet Genomics. janv, vol.22, issue.1, 2012.

, polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients, J Clin Psychiatry. mai, vol.68, issue.5, p.697704, 2007.

V. Ozdemir, W. Kalow, A. B. Okey, M. S. Lam, L. J. Albers et al., Treatmentresistance to clozapine in association with ultrarapid CYP1A2 activity and the C->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine, J Clin Psychopharmacol. déc, vol.21, issue.6, p.6037, 2001.

C. B. Eap, S. Bender, J. Sirot, E. Cucchia, G. Jonzier-perey et al., Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene, J Clin Psychopharmacol. avr, vol.24, issue.2, p.2149, 2004.

F. Papetti, V. Morel-pingault, V. Buisse, L. Maziere, M. Banayan et al., Clozapine-resistant schizophrenia related to an increased metabolism and benefit of fluvoxamine

L. 'encephale, The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients, Ann Clin Biochem. 1 mai, vol.33, issue.5, p.2169, 2005.

B. Laika, S. Leucht, S. Heres, H. Schneider, and W. Steimer, Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome, Pharmacogenomics J. févr, vol.10, issue.1, p.209, 2010.

E. Skogh, F. Bengtsson, and C. Nordin, Could Discontinuing Smoking Be Hazardous for Patients Administered Clozapine Medication? A Case Report, Ther Drug Monit, vol.21, p.5802, 1999.

, Annexe 3. Principaux cytochromes impliqués dans le métabolisme des antipsychotiques

, Amisulpride n'est métabolisé par aucun de ces cytochromes (?=voie de métabolisation principale ; ? =voie de métabolisation secondaire

, ! = métabolite actif)(30)